Alkermes plc. (ALKS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Alkermes plc.'s filing signal turned negative.

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. The company exclusively commercializes ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL in the U.S., and recently acquired LUMRYZ in February 2026. Alkermes also earns manufacturing and royalty revenues from licensed products, including the long-acting INVEGA products and VUMERITY, through collaborations with Janssen and Biogen, respectively. Headquartered in Ireland, the company maintains a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.

Revenue is driven by sales of proprietary commercial products in the U.S., including ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL, and LUMRYZ. Additionally, the company generates manufacturing and royalty revenues from its collaborative arrangements with third parties, such as Janssen and Biogen, for products utilizing its proprietary technologies or licensed products.